Foundation Medicine

Foundation Medicine is a molecular information company developing clinical diagnostic tests that facilitate personalized cancer therapies. It provides clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies and sarcomas that provide a comprehensive genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. The company also offers a molecular information platform that aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.
TypeSubsidiary
Parent CompanyRoche
HQCambridge, MA, US
Founded2010
Websitefoundationmedicine.com
Cybersecurity ratingBMore
Foundation Medicine was founded in 2010 and is headquartered in Cambridge, MA, US

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Foundation Medicine

Cindy Perettie

Cindy Perettie

Chief Executive Officer
Brian Alexander

Brian Alexander

Chief Medical Officer
Konstantin Fiedler

Konstantin Fiedler

Chief Operating Officer
Tim Kelly

Tim Kelly

Chief Financial Officer
Jeffrey Ross

Jeffrey Ross

Medical Director
Amy Lin

Amy Lin

Senior Vice President, Head of Global Portfolio Strategy
Show more

Foundation Medicine Office Locations

Foundation Medicine has offices in Cambridge, Morrisville, Palo Alto, San Diego and in 1 other location
Cambridge, MA, US (HQ)
150 Second St
Morrisville, NC, US
7010 Kit Creek Rd
Palo Alto, CA, US
525 University Ave #100
San Diego, CA, US
4545 Towne Centre Ct
Penzberg, DE
Nonnenwald 2/building 433
Show all (5)

Foundation Medicine Financials and Metrics

Summary Metrics

Founding Date

2010

Total Funding

$96.5 m

Investors

In total, Foundation Medicine had raised $96.5 m. Foundation Medicine is a subsidiary of Roche

Foundation Medicine Revenue

Foundation Medicine's revenue was reported to be $152.9 m in FY, 2017
USDFY, 2017

Revenue

152.9m

Cost of goods sold

85.3m

Gross profit

67.6m

Gross profit Margin, %

44%
USDFY, 2017

Cash

71.4m

Accounts Receivable

20.0m

Inventories

13.2m

Current Assets

123.8m
USDFY, 2017

Net Income

(161.5m)

Depreciation and Amortization

18.5m

Inventories

(2.6m)

Accounts Payable

8.4m
USDFY, 2017

Revenue/Employee

285.8k

Debt/Equity

1.9 x

Debt/Assets

0.4 x

Financial Leverage

5.3 x
Show all financial metrics

Foundation Medicine Operating Metrics

Jan, 2021

Biopharma Partners

50

Patient Profiles in Clinico-Genomic Database

55 k

Patients Tested to Date

400 k

Peer-Reviewed Publications

500
Show all operating metrics

Foundation Medicine Acquisitions / Subsidiaries

Company NameDateDeal Size
Lexent BioJune 12, 2020

Foundation Medicine Revenue Breakdown

Embed Graph

Foundation Medicine revenue breakdown by geographic segment: 92.8% from United States and 7.2% from Other

Foundation Medicine Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

SecurityScorecard logo

Foundation Medicine Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Foundation Medicine Online and Social Media Presence

Embed Graph

Foundation Medicine Company Culture

  • Overall Culture

    B+

    73/100

  • CEO Rating

    A-

    75/100

  • Compensation

    B

    74/100

  • Diversity

    B-

    71/100

Learn more on Comparably

Foundation Medicine News and Updates

TwinStrand Biosciences Licenses Duplex Sequencing Technology to Foundation Medicine

SEATTLE, Nov. 18, 2020 /PRNewswire/ -- TwinStrand Biosciences today announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction...

UPDATE 1-Bayer to work with Foundation Medicine on cancer patient screening

* Genetic sequencing test seen as vital to secure market uptake

Global $85.5 Billion Precision Medicine (Diagnostics/Therapeutics) Market to 2025 - Key Players are GE Healthcare; Abbott Lab, Precision Biologics, Foundation Medicine, Illumina and IBM Watson

DUBLIN, Nov. 16, 2018 /PRNewswire/ -- The "Precision Medicine (Diagnostics/Therapeutics) Market Analysis Report By Application (Genetic Tests, Esoteric Tests, Pharmaceuticals, Medical Devices), By End Use, And Segment Forecasts, 2018 - 2025" report has been added to...

UPDATE 2-Roche pays $2.4 bln for rest of cancer expert Foundation Medicine

* Echoes past biotech buy-outs at Flat Iron and Genentech (Adds more on personalised cancer care, analyst comment)

UPDATE 1-Roche to pay $2.4 bln to buy rest of Foundation Medicine

ZURICH, June 19 (Reuters) - Swiss drugmaker Roche Holding AG has agreed to pay $137 per share to buy the rest of Foundation Medicine (FMI), a $2.4 billion transaction that values the U.S. genomic profiling group at $5.3 billion, the partners said on Tuesday.

Foundation Medicine Blogs

The Promise and Potential of Genomic Data for the Future of Precision Medicine | Foundation Medicine

Precision medicine in cancer care is the product of a transformative change in our collective thinking, driven by a deepening understanding of genomics and the biology of disease.  But that transforma...

As Genomic Profiling Becomes Standard of Care, Real-World Genomic Data Comes of Age | Foundation Medicine

The longstanding partnership between Foundation Medicine and Flatiron Health is grounded in a shared belief that harnessing the continuous flow of real-world data in real time, and in the right way, c...

Comprehensive Genomic Profiling as the Driver of Change in Rarer Cancers | Foundation Medicine

Precision medicine has helped revolutionize the way we diagnose and treat cancer. The unprecedented volume of data that tumor mutation testing, particularly comprehensive genomic profiling (CGP), deli...

Companion Diagnostics Explained: Their Critical Role in Cancer Care and Our Latest Approvals | Foundation Medicine

NOW FDA APPROVED: OUR NEWEST* COMPANION DIAGNOSTIC INDICATIONS Below are the newest* additions to our roster of companion diagnostic approvals across multiple cancers and our portfolio of FDA-approved...

A New Collaboration to Build the Future of Cancer Care

Our mission at Foundation Medicine is to transform cancer care for patients. We believe that we can redefine the way patients are diagnosed and treated through a deeper understanding of cancer, shapin...

Helping More Patients Benefit from Precision Cancer Care with A Portfolio of Genomic Testing Options | Foundation Medicine

Foundation Medicine has been a pioneer in leveraging deep genomic insights to inform cancer treatment decisions. Our mission is to ensure every patient benefits from the latest science at the time of ...
Show more

Foundation Medicine Frequently Asked Questions

  • When was Foundation Medicine founded?

    Foundation Medicine was founded in 2010.

  • Who are Foundation Medicine key executives?

    Foundation Medicine's key executives are Cindy Perettie, Brian Alexander and Konstantin Fiedler.

  • How many employees does Foundation Medicine have?

    Foundation Medicine has 1,675 employees.

  • What is Foundation Medicine revenue?

    Latest Foundation Medicine annual revenue is $152.9 m.

  • What is Foundation Medicine revenue per employee?

    Latest Foundation Medicine revenue per employee is $91.3 k.

  • Who are Foundation Medicine competitors?

    Competitors of Foundation Medicine include Biodesix, Flatiron Health and Myriad Genetics.

  • Where is Foundation Medicine headquarters?

    Foundation Medicine headquarters is located at 150 Second St, Cambridge.

  • Where are Foundation Medicine offices?

    Foundation Medicine has offices in Cambridge, Morrisville, Palo Alto, San Diego and in 1 other location.

  • How many offices does Foundation Medicine have?

    Foundation Medicine has 5 offices.